TY - JOUR
T1 - Potential impact of maternal vaccination on life-threatening respiratory syncytial virus infection during infancy
AU - Scheltema, Nienke M.
AU - Kavelaars, Xynthia M.
AU - Thorburn, Kentigern
AU - Hennus, Marije P.
AU - van Woensel, Job B.
AU - van der Ent, Cornelis K.
AU - Borghans, José A. M.
AU - Bont, Louis J.
AU - Drylewicz, Julia
PY - 2018
Y1 - 2018
N2 - Background: Respiratory syncytial virus (RSV) infection is an important cause of infant mortality. Here, we estimated the potential impact of maternal vaccination against RSV on life-threatening RSV infection in infants. Methods: We developed a mathematical model for maternal vaccine-induced antibody dynamics and used characteristics of a maternal RSV vaccine currently in phase 3 of clinical development. The model was applied to data from two cohorts of children younger than 12 months with RSV-related paediatric intensive care unit (PICU) admission in the United Kingdom (n = 370) and the Netherlands (n = 167), and a cohort of 211 children younger than 12 months with RSV-related in-hospital death from 20 countries worldwide. Results: Our model predicted that, depending on vaccine efficiency, maternal vaccination at 30 weeks’ gestational age could have prevented 62–75% of RSV-related PICU admissions in the United Kingdom and 76–87% in the Netherlands. For the global mortality cohort, the model predicted that maternal vaccination could have prevented 29–48% of RSV-related in-hospital deaths. Preterm children and children with comorbidities were predicted to benefit less than (healthy) term children. Conclusions: Maternal vaccination against RSV may substantially decrease life-threatening RSV infections in infants.
AB - Background: Respiratory syncytial virus (RSV) infection is an important cause of infant mortality. Here, we estimated the potential impact of maternal vaccination against RSV on life-threatening RSV infection in infants. Methods: We developed a mathematical model for maternal vaccine-induced antibody dynamics and used characteristics of a maternal RSV vaccine currently in phase 3 of clinical development. The model was applied to data from two cohorts of children younger than 12 months with RSV-related paediatric intensive care unit (PICU) admission in the United Kingdom (n = 370) and the Netherlands (n = 167), and a cohort of 211 children younger than 12 months with RSV-related in-hospital death from 20 countries worldwide. Results: Our model predicted that, depending on vaccine efficiency, maternal vaccination at 30 weeks’ gestational age could have prevented 62–75% of RSV-related PICU admissions in the United Kingdom and 76–87% in the Netherlands. For the global mortality cohort, the model predicted that maternal vaccination could have prevented 29–48% of RSV-related in-hospital deaths. Preterm children and children with comorbidities were predicted to benefit less than (healthy) term children. Conclusions: Maternal vaccination against RSV may substantially decrease life-threatening RSV infections in infants.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85048881020&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/29941327
U2 - https://doi.org/10.1016/j.vaccine.2018.06.021
DO - https://doi.org/10.1016/j.vaccine.2018.06.021
M3 - Article
C2 - 29941327
SN - 0264-410X
VL - 36
SP - 4693
EP - 4700
JO - Vaccine
JF - Vaccine
IS - 31
ER -